Cargando…

Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome

INTRODUCTION: Treatment-resistant nephrotic syndrome is a rare form of glomerular disease that occurs in children and adults. No Food and Drug Administration−approved treatments consistently achieve remission of proteinuria and preservation of kidney function. CD80 (B7-1) can be expressed on injured...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trachtman, Howard, Gipson, Debbie S., Somers, Michael, Spino, Cathie, Adler, Sharon, Holzman, Lawrence, Kopp, Jeffrey B., Sedor, John, Overfield, Sandra, Elegbe, Ayanbola, Maldonado, Michael, Greka, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762951/ https://www.ncbi.nlm.nih.gov/pubmed/29340321 http://dx.doi.org/10.1016/j.ekir.2017.08.013

Ejemplares similares

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Plasma Zonulin Levels in Childhood Nephrotic Syndrome
por: Trachtman, Howard, et al.
Publicado: (2019)

Developing an Edema Clinician-Reported Outcome Measure for Nephrotic Syndrome
por: Gipson, Debbie S., et al.
Publicado: (2023)

Changing the Paradigm for the Treatment and Development of New Therapies for FSGS
por: Spino, Cathie, et al.
Publicado: (2016)

Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multi-disciplinary approach
por: Gadegbeku, Crystal A., et al.
Publicado: (2013)

NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome
por: Gipson, Debbie S., et al.
Publicado: (2017)

Gluten-Free Diet in Childhood Difficult-to-Treat Nephrotic Syndrome: A Pilot Feasibility Study
por: Srivastava, Tarak, et al.
Publicado: (2022)

Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design
por: Trachtman, Howard, et al.
Publicado: (2011)

Machine-learning classification identifies patients with early systemic sclerosis as abatacept responders via CD28 pathway modulation
por: Mehta, Bhaven K., et al.
Publicado: (2022)

Restless Legs Syndrome in Pediatric Patients With Nephrotic Syndrome
por: Cheung, Victoria, et al.
Publicado: (2015)

Text Messaging for Disease Monitoring in Childhood Nephrotic Syndrome
por: Wang, Chia-shi, et al.
Publicado: (2019)

The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network
por: Troost, Jonathan P, et al.
Publicado: (2019)

Responsiveness of the PROMIS® measures to changes in disease status among pediatric nephrotic syndrome patients: a Midwest pediatric nephrology consortium study
por: Selewski, David T., et al.
Publicado: (2017)

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
por: Trautmann, Agnes, et al.
Publicado: (2022)

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group
por: Trachtman, Howard, et al.
Publicado: (2015)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
por: Komers, Radko, et al.
Publicado: (2017)

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
por: Emery, P, et al.
Publicado: (2009)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Urinary Epidermal Growth Factor as a Marker of Disease Progression in Children With Nephrotic Syndrome
por: Gipson, Debbie S., et al.
Publicado: (2019)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Pediatric Immunization Practices in Nephrotic Syndrome: An Assessment of Provider and Parental Knowledge
por: Tran, Cheryl L., et al.
Publicado: (2021)

Brief Report: Estimating Disease Activity Using Multi‐Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab
por: Fleischmann, Roy, et al.
Publicado: (2016)

Experience with abatacept in refractory lupus nephritis
por: Calatayud, Emma, et al.
Publicado: (2023)

Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
por: Jabado, Omar, et al.
Publicado: (2021)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Abatacept in difficult-to-treat juvenile idiopathic arthritis
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2008)

Abatacept as a Therapeutic Option for Rheumatoid Vasculitis
por: Al Attar, Layth, et al.
Publicado: (2018)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
por: Weinblatt, Michael E, et al.
Publicado: (2013)

Comparing Kidney Health Outcomes in Children, Adolescents, and Adults With Focal Segmental Glomerulosclerosis
por: Gipson, Debbie S., et al.
Publicado: (2022)

Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group
por: Peyser, Alexandra, et al.
Publicado: (2010)

Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
por: Truchetet, Marie-Elise, et al.
Publicado: (2016)

Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
por: Fleischmann, Roy, et al.
Publicado: (2019)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
por: Katargina, LA, et al.
Publicado: (2011)

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis
por: Köller, Marcus D.
Publicado: (2007)

PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis
por: Moretti, D, et al.
Publicado: (2013)

Abatacept in psoriatic arthritis: Case report and short review
por: Ursini, Francesco, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_veou5f8a077mv5fk63goltfn4h